Codexis Announces Byron Dorgan to Retire from Board of Directors
Codexis (NASDAQ: CDXS) announced that Byron Dorgan will retire from its Board of Directors at the 2025 Annual Meeting of Stockholders. Dorgan, who joined the Board in 2011 and served as Chairman from 2021 through 2024, currently chairs the Nominating and Corporate Governance Committee.
Following his departure, Dorgan will continue as a consultant to Codexis for one year. The company will reduce its Board seats from ten to nine. During his tenure, Dorgan contributed to Codexis's transformation into a leading therapeutics manufacturing company, particularly in advancing solutions like the ECO Synthesis platform.
Codexis (NASDAQ: CDXS) ha annunciato che Byron Dorgan si ritirerà dal suo Consiglio di Amministrazione durante l'Assemblea Annuale degli Azionisti del 2025. Dorgan, che è entrato a far parte del Consiglio nel 2011 e ha ricoperto il ruolo di Presidente dal 2021 al 2024, attualmente presiede il Comitato per le Nomine e la Governance Aziendale.
Dopo la sua partenza, Dorgan continuerà a lavorare come consulente per Codexis per un anno. L'azienda ridurrà i suoi posti nel Consiglio da dieci a nove. Durante il suo mandato, Dorgan ha contribuito alla trasformazione di Codexis in un'azienda leader nella produzione di terapie, in particolare nel progresso di soluzioni come la piattaforma ECO Synthesis.
Codexis (NASDAQ: CDXS) anunció que Byron Dorgan se retirará de su Junta Directiva en la Reunión Anual de Accionistas de 2025. Dorgan, quien se unió a la Junta en 2011 y se desempeñó como Presidente de 2021 a 2024, actualmente preside el Comité de Nominaciones y Gobernanza Corporativa.
Tras su salida, Dorgan continuará como consultor de Codexis durante un año. La empresa reducirá sus asientos en la Junta de diez a nueve. Durante su mandato, Dorgan contribuyó a la transformación de Codexis en una empresa líder en fabricación de terapias, especialmente en el avance de soluciones como la plataforma ECO Synthesis.
Codexis (NASDAQ: CDXS)는 Byron Dorgan이 2025년 주주 연례 회의에서 이사회에서 은퇴할 것이라고 발표했습니다. Dorgan은 2011년에 이사회에 합류하였으며 2021년부터 2024년까지 의장을 역임하였고, 현재는 추천 및 기업 거버넌스 위원회를 주재하고 있습니다.
그의 퇴임 후, Dorgan은 Codexis의 컨설턴트로 1년간 계속 일할 것입니다. 회사는 이사회 자리를 10개에서 9개로 줄일 예정입니다. 그의 재임 기간 동안 Dorgan은 Codexis가 주요 치료제 제조 회사로 변화하는 데 기여하였으며, 특히 ECO 합성 플랫폼과 같은 솔루션을 발전시키는 데 중요한 역할을 했습니다.
Codexis (NASDAQ: CDXS) a annoncé que Byron Dorgan se retirera de son Conseil d'Administration lors de l'Assemblée Générale Annuelle des Actionnaires de 2025. Dorgan, qui a rejoint le Conseil en 2011 et a été Président de 2021 à 2024, préside actuellement le Comité des Nominations et de la Gouvernance d'Entreprise.
Après son départ, Dorgan continuera en tant que consultant pour Codexis pendant un an. L'entreprise réduira le nombre de ses sièges au Conseil de dix à neuf. Pendant son mandat, Dorgan a contribué à la transformation de Codexis en une entreprise leader dans la fabrication de thérapies, notamment en faisant progresser des solutions comme la plateforme ECO Synthesis.
Codexis (NASDAQ: CDXS) gab bekannt, dass Byron Dorgan bei der Jahreshauptversammlung der Aktionäre 2025 aus dem Vorstand ausscheiden wird. Dorgan, der 2011 in den Vorstand eintrat und von 2021 bis 2024 als Vorsitzender diente, leitet derzeit den Nominierungs- und Corporate Governance-Ausschuss.
Nach seinem Ausscheiden wird Dorgan ein Jahr lang weiterhin als Berater für Codexis tätig sein. Das Unternehmen wird die Anzahl der Sitze im Vorstand von zehn auf neun reduzieren. Während seiner Amtszeit trug Dorgan zur Transformation von Codexis in ein führendes Unternehmen in der Herstellung von Therapeutika bei, insbesondere durch die Förderung von Lösungen wie der ECO Synthesis-Plattform.
- Planned smooth transition with one-year consulting arrangement post-retirement
- Board size optimization from 10 to 9 members, potentially improving efficiency
- Loss of long-term board member with 15 years of company experience
- Departure of recent Board Chairman (2021-2024) may impact leadership continuity
REDWOOD CITY, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that Byron Dorgan will retire from the Company’s Board of Directors when his current term ends at the 2025 Annual Meeting of Stockholders. Mr. Dorgan joined the Board in 2011, served as Chairman from 2021 through 2024, and currently serves as the Chair of the Nominating and Corporate Governance Committee. He will remain a consultant to Codexis for one year following his departure from the Board.
“On behalf of the entire Board of Directors, I want to express our appreciation for Byron’s valuable guidance and leadership as we collaborated to transform Codexis into a leading therapeutics manufacturing company,” said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. “We are grateful for his longstanding dedication to the Company and wish him the very best.”
Mr. Dorgan added, “It has been a privilege to serve on the Codexis Board alongside a group of bright and passionate directors for almost 15 years. I am incredibly proud of our progress toward advancing innovative solutions like the ECO Synthesis platform, and I look forward to following Codexis through its exciting next chapter.”
With this change, Codexis will reduce the number of seats on its Board of Directors from ten to nine.
About Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “suggest,” “target,” “on track,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. To the extent that statements contained in this press release are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management, including but not limited to statements regarding the potential of the ECO Synthesis™ platform, and it providing an opportunity for Codexis to efficiently capture meaningful market share; expectations regarding Codexis meeting its technical and commercial milestones regarding the ECO Synthesis™ platform; and expectations regarding the potential of and future demand for RNAi therapeutics, and whether Codexis will be able to capitalize on such demand. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Codexis’ control and that could materially affect actual results. Factors that could materially affect actual results include, among others: Codexis’ dependence on its licensees and collaborators; if any of its collaborators terminate their development programs under their respective license agreements with Codexis; Codexis may need additional capital in the future in order to expand its business; if Codexis is unable to successfully develop and commercialize new technology such as its ECO Synthesis™ platform and its dsRNA ligase; Codexis dependence on a limited number of products and customers, and potential adverse effects to Codexis’ business if its customers’ products are not received well in the markets; if competitors and potential competitors who have greater resources and experience than Codexis develop products and technologies that make Codexis’ products and technologies obsolete; if Codexis is unable to accurately forecast financial and operational performance; and market and economic conditions may negatively impact Codexis business, financial condition and share price. Additional information about factors that could materially affect actual results can be found in Codexis’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 27, 2025 and in Codexis’ Quarterly Report on Form 10-Q filed with the SEC on October 31, 2024, including under the caption “Risk Factors,” and in Codexis’ other periodic reports filed with the SEC. Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
For More Information
Investor Contact
Carrie McKim
(336) 608-9706
ir@codexis.com
FAQ
When will Byron Dorgan retire from Codexis (CDXS) Board of Directors?
How long has Byron Dorgan served on the Codexis (CDXS) Board?
What will be the size of Codexis (CDXS) Board after Dorgan's retirement?
What role will Byron Dorgan maintain with Codexis (CDXS) after his Board retirement?
